Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Postmenopausal breast cancer: a best endocrine strategy?

Postmenopausal, oestrogen receptor (ER)-positive breast cancers account for the majority of the 1·7 million breast cancers diagnosed annually worldwide. Adjuvant endocrine therapy dramatically improves survival among such patients, making it vital to understand the best treatment strategies. For decades, the Early Breast Cancer Trialists’ Collaborative Group meta-analyses have informed clinical practice in early-stage breast cancer, and the present report1 in The Lancet on over 30 000 women treated with adjuvant tamoxifen, aromatase inhibitors, or a sequence of those agents continues that tradition.